Asthma is an airway disease highly prevalent in westernized countries and of unknown aetiology. Often asthma is associated with atopy, but not all atopic individuals are asthmatics. Some asthma patients outgrow symptoms, whereas many others acquire asthma later in life. Still other patients suffer from asthma their entire life. How can we explain these different patterns? It may be asthma should be regarded as the clinical manifestation of a group of diseases with similar pathology due to a common factor. In this perspective we propose that an aberrant phenotype of airway smooth muscle (ASM) cells could be sufficient to explain the pathology of asthma. We will argue an abnormal ASM cell is a prerequisite to the development of asthma. Our postulate is that inadequate levels of C/EBPα, a protein that is pivotal for the suppression of both inflammation and proliferation responses, confer on ASM cells an activated phenotype that is more susceptible to mitogenic and contractile stimuli.
Introduction
Smooth muscle cells surround the airways from the trachea down to the alveolar ducts. Inhalation of chemical irritants, smoke or dust, or activation of arterial chemoreceptors, as well as release of inflammatory mediators such as histamine, thromboxane and leukotrienes can induce constriction of the smooth muscle. In asthma patients the constriction caused by these and other (nonspecific) stimuli is exaggerated and abnormal. Many years of intense scrutiny have revealed that the airways of asthma patients are characterised by infiltrates of mast cells, eosinophils, macrophages and T lymphocytes. In addition, the asthmatic lung shows persistent airway wall remodelling. Despite this knowledge, we still cannot answer the pivotal question that drives asthma research: Why do the airways of asthma patients constrict so forcefully in response to a wide range of stimuli? Airway inflammation might be an important factor that is linked to the severity of asthma attacks, but the airway inflammation does not have to be T cell mediated, per se. Based on our results in human ASM cells we hypothesise that the lack of a crucial transcription factor, CCAAT/enhancer binding protein-α (C/EBPα) results from faulty translation of the respective mRNA which in turn can be linked to most of the documented features of the pathology of asthma. Some of the results of these studies have been previously reported in the form of an abstract (1) .
Is asthma merely an inflammatory disease?
Two decades ago, Mosmann and Coffman reported that Th1 and Th2 cells determined the type of immune response in mice (2) . Soon, it was established that Th2 cells in mice models produced GM-CSF, interleukin (IL)-3, IL-4, IL-5, IL-9 and IL-13, and hence regulated immunoglobulin E (IgE) synthesis as well as the production, recruitment and activation of mast cells and eosinophils. Most of the relevant cytokines can also be produced by other cell types present in the lung, including ASM cells (table 1) .
The excess of Th2 cells and/or their soluble mediators potentially explained many inflammatory phenomena of (allergic) asthma in both animals and humans, including eosinophilia and atopy. Studies in humans showed that Th2 cells and their respective cytokines were more abundant in serum and bronchoalveolar lavage fluid of (allergic) asthma patients compared to controls (3-6). These findings led to the general acceptance of the postulate that asthma involved chronic inflammation of the lung; probably the result of an increased Th2-like response with high levels of IL-4, IL-5 and IL-13 (7).
There must however be more to asthma than Th2 cell mediated inflammation. T cells contribute to inflammatory responses, but their role in asthma could be limited. T cell numbers do not correlate with severity or persistence of asthma and are also not associated with exacerbations or diminished responsiveness to steroids. In this context it is important to note that studies using cyclosporine to treat (severe) asthma raised questions about the role of T cells in the pathogenesis of asthma. Cyclosporine blocks T cell activation and inhibits the release of inflammatory mediators, such as IL-2, IL-4 and IL-5 (8-10). The studies showed that cyclosporine blocked the late asthmatic reaction, but not the early asthmatic response (11, 12). Such findings suggest that the early asthmatic response is not T cell mediated, but rather implicate direct effects of inflammatory mediators on ASM contraction that cannot be counteracted by blocking T cell activity.
That asthma is not merely Th2 inflammation is also evident from additional clinical trials. Administration of anti-IL-5 monoclonal antibodies effectively reduced eosinophils in the airways and in peripheral blood in asthma patients, but did not relieve asthma symptoms or bronchial hyper-responsiveness (13, 14) .
Recombinant soluble IL-4 receptor administration has been somewhat more successful, but still did not meet the expectations of complete recovery from asthma symptoms (13) . This shows that Th2 inflammation alone is insufficient to explain the hyper-responsiveness of the airways of asthma patients. Therefore, it remains an open question as to why the airways of asthma patients exhibit such abnormal behaviour.
Is it really airway inflammation that underlies the abnormal responsiveness of the ASM cells, or could it be the other way around? Are the resident ASM cells of asthma patients abnormal in their behaviour and can they initiate an (Th2-like) inflammatory response? The ASM cell is a rich source of pro-inflammatory cytokines, chemokines and growth factors (15, 16) , and this fact alone indicates that the ASM cell may fulfil a more active role in inflammatory lung diseases than currently envisioned.
The airways in asthma
The histology of cross sections of the airways of asthma patients is distinctly different from that of healthy subjects. Epithelial goblet cell hypertrophy and hyperplasia, mucus plugs, sub-epithelial fibrosis and increased vascularization of the airway wall are present. The most striking feature is the increased bulk of ASM cells (figure 1). The increase in muscle mass is quite marked in patients who have died of asthma, but can also be found in bronchial-biopsies taken from patients with mild or moderate asthma, and is thought to result from ongoing airway inflammation.
Numerous growth factors and cytokines that regulate the activity and proliferation of ASM cells are found in asthmatic airways. Bronchoalveolar lavage fluid of asthma patients was found to increase proliferation of normal human ASM cells, an effect that was further augmented after allergen challenge, suggesting a direct activating effect of allergens on ASM cells (17) . Recently it was demonstrated that Der p 1, a major house dust mite allergen, activated the ERK1/2 signalling cascade in ASM cells, showing that allergens may indeed have a direct proasthmatic effect on ASM cells (18) . In addition, we observed that incubation of normal human ASM cells with allergic serum and subsequent exposure to allergen resulted in an increased proliferation and enhanced expression of c-fos and c-jun, the two components that form the activator protein 1 (AP-1) transcription factor that is associated with cell proliferation (unpublished observations). Normal ASM cells may also become more responsive to activation and/or growth promoting cytokines as the expression of cytokine receptors is increased after exposure to atopic asthmatic serum (19) . Considering the mitogenic and priming nature of the mediators released by inflamed tissue, it is not too surprising that they can induce ASM cell proliferation and thus may contribute to ASM cell hyperplasia. However, the cellular source of these inflammatory mediators is largely a matter of speculation. Based mainly on the Th2 paradigm, several cell types have been suggested, including Th2 cells, eosinophils, mast cells, and epithelial cells (table 1). We will argue that the biology of ASM cells suggests that this cell may be the key player in the pathogenesis of asthma, explaining both inflammation and remodelling.
The abnormal ASM cells of asthma patients
Because ASM cells are directly responsible for airway constriction, it is reasonable to propose that an ASM cell abnormality could underlie the airway hyper-responsiveness of asthma patients (20) . It has been difficult to assess ASM cell function in asthma because it was thought too risky to obtain these cells from asthma patients for culture in the laboratory. Recently, through the willingness to do bronchoscopy and biopsy in asthmatic volunteers it has become 8 possible to compare ASM cells of healthy controls with that of asthma patients.
Our group was the first to provide evidence for an intrinsic abnormality of ASM cells obtained from asthma patients. In 2001, we reported that ASM cells from asthmatic patients proliferate significantly faster than cells from control subjects as assessed by manual cell counts, [ 3 H]-thymidine incorporation, and fluorescent-activated cell sorting (FACS) analysis of their DNA content (21) . This increased in vitro proliferation rate may be responsible in vivo for the increase in ASM mass in the airways of asthma patients (22) . A recent report showed that hyperthermal removal of the ASM bundles significantly reduced asthma symptoms and improved lung function (23) . It remains to be established, however, whether removal of ASM bundles reduces airway inflammation as well.
There are more differences between ASM cells of healthy and asthmatic subjects, however. In response to transforming growth factor (TGF)-β, ASM cells of asthma patients produce more connective tissue growth factor (CTGF), an important contributor to the increased deposition of extracellular matrix (24) .
Cultured ASM cells of asthma patients produce less prostaglandin E 2 (PGE 2 ) as a result of lower COX2 expression (25) , but, probably as a compensatory mechanism, are more sensitive to PGE 2 due to increased numbers of Eprostanoid receptors (26) . PGE 2 directly counteracts airway constriction (27, 28) .
Reduced levels of PGE 2 could thus result in less airway relaxation, or lower the threshold for other substances that initiate ASM cell contraction. Finally, our group showed that relative to controls, ASM cells of asthma patients released more IL-6 upon stimulation with recombinant OX40, a molecule present on activated T cells, indicating an interaction between these cells in the airways of asthma patients (29) . Together, these observations suggest that ASM cells from asthma patients have an activated phenotype that may be attributed to an intrinsic (or acquired) abnormality. The question is now whether a single factor could account for all these abnormalities of the asthmatic ASM cell. If such a factor exists it must have a broad range of action.
Is C/EBPα the asthma protein?
C/EBPα is an important regulator of cell proliferation and inflammation. It has several domains that bind to and influence the action of several transcription factors and cyclin dependent kinases, and it has a domain for DNA binding (30, 31) . C/EBPα is expressed as two isoforms, p30 and p42, which are regulated at the posttranscriptional level through alternative translation initiation sites present in the messenger RNA (30) . In human smooth muscle cells and fibroblasts, C/EBPα determines the rate of proliferation through induction of the cell cycle inhibitor p21 waf1/cip1 (32) (33) (34) . In normal ASM cells steroids and β-mimetics also exert their inhibitory effects via C/EBPα in a complex with the glucocorticoid receptor (GR) that activates the p21 waf1/cip1 gene (33) . A combination of steroids and β-mimetics induce an even faster and persistent activation of the C/EBPα-GR complex and p21 waf1/cip1 (33) . Apparently, cell cycle repression by these drugs requires the simultaneous activation of both the GR and C/EBPα.
We have recently reported that ASM cells of asthma patients lack the antiproliferative isoform of C/EBPα, and, because the complex with the GR cannot be formed, the p21 waf1/cip1 gene cannot be sufficiently induced (35) 
C/EBPα and airway inflammation
The nuclear factor (NF)-κB is an important transcription factor required to induce an inflammatory response through the activation of proinflammatory genes leading to the increased synthesis of cytokines, adhesion molecules, chemokines and growth factors (36, 37) . C/EBPα has the potential to silence this inflammatory response through interference with NF-κB-driven gene expression (38, 39) . Considering these interactions, it is not surprising that NF-κB has been implicated in asthma-associated inflammation (40, 41) . ASM cells have the capacity to produce many cytokines that are thought important in asthma, including interleukins 1, 2, 5, 6, 11, and 12 (8, 9). ASM cells also produce thymus and activation-regulated chemokine (TARC) (36) . TARC selectively induces the migration of Th2 cells and is up-regulated in the airways of asthmatic patients (37) . The expression of these cytokines (31) and TARC (37) production critically depends on C/EBPs (48).
C/EBPα and airway hyper-responsiveness
An increase in the contractile properties of the airways is likely a major 
Discussion and future directions
The goal of this perspective is to encourage scientists and physicians to reconsider the role of the ASM cell in the pathogenesis of asthma. We propose that the ASM cell could be the most important cell type in asthma pathology. Not only does the ASM cell causes the airways to constrict; ASM cells of asthma patients also proliferate faster, produce more cytokines and growth factors, and contract to a greater degree. In this perspective we have summarized the evidence that the ASM cell has the ability to induce and sustain an environment that promotes airway inflammation and remodelling. We have also argued that the absence of the full length C/EBPα protein, which is a feature of ASM cells of asthma patients, potentially explains most of the pathological and clinical features of asthma, including inflammation, remodeling and airway hyperresponsiveness. At present it is not known why the ASM cells of asthma patients have reduced levels of C/EBPα, but our observations strongly suggest that it is not due to a diminished transcription of the CEBPA gene. Rather, the translation of the messenger RNA into the full length protein seems to be disturbed (1) . In addition, our most recent studies identified the lack of the C/EBPα protein as specific for ASM cells of asthma patients, while COPD and emphysema patients expressed normal levels. The presence or absence of C/EBPα in ASM cells may therefore also become helpful in distinguishing between asthma and COPD at an early stage of the diseases (table 2) .
Of course, there are many questions that still have to be addressed, for example: 
